Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

NCT04774926 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Brolucizumab

Sponsor

Novartis Pharmaceuticals